

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:  
Hans Ulrich STILZ et al.

Confirmation No.:

Serial No.: Unassigned

Art Unit: Unassigned

Filed: Concurrently Herewith

Examiner: Unassigned

For: 5-MEMBERED RING HETEROCYCLES AS INHIBITORS OF LEUCOCYTE  
ADHESION AND AS VLA-4 ANTAGONISTS

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §1.56 and 37 CFR §1.97

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08A is a listing of documents known to applicants in order to comply with applicants' duty of disclosure pursuant to 37 C.F.R. §1.56.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or is considered to be material to patentability as defined in 37 C.F.R. §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* prior art reference against the claims of the present application.

The documents submitted herewith on Form PTO/SB/08A, lists the documents cited by or submitted to the Patent Office in parent application Serial No. 08/971,960 filed November 17, 1997.


As provided in 37 C.F.R. §1.98(d), copies of the documents are not being provided since they were previously cited by or submitted to the Patent Office in parent application Serial No. 08/971,960 filed November 17, 1997.

The instant Information Disclosure Statement is being filed in compliance with 37 CFR §1.97(b) prior to the mailing date of the first official action, therefore, no fee is required in connection with its filing. However, the Commissioner is hereby authorized to charge any deficiency or to credit any overpayment to Deposit Account No. 08-1641.

Applicants respectfully request that the listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO-SB/08A be returned in accordance with M.P.E.P. §609.

Respectfully submitted,

Oct 24, 2003  
Date

  
Patricia D. Granados  
Reg. No. 33,683

**Customer ID No. 26633**  
HELLER EHRMAN WHITE & McAULIFFE LLP  
1666 K Street, N.W., Suite 300  
Washington, DC 20006  
Telephone: (202) 912-2000  
Facsimile: (202) 912-2020

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
Sheet	1	of	3	Application Number	Unassigned
				Filing Date	Concurrently Herewith
				First Named Inventor	Hans Ulrich STILZ et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	38005-0190

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	A01	5,389,614		Koenig at al.	2/95	
	A02	5,397,796		Zoller et al.	3/95	
	A03	5,424,293		Zoller at al.	6/95	
	A04	5,554,594		Zoller et al.	9/96	
	A05	5,658,935		Klingler at al.	8/97	
	A06	5,424,293		Zoeller et al.	6/95	
	A07	5,998,447		Stilz et al.	12/7/1999	
	A08	6,034,238		Wehner et al.	3/2000	
	A09	6,218,415		Wehner et al.	4/2001	
	A10	6,294,562		Stilz et al.	9/2001	
	A11	6,005,117		Wehner et al.	12/1999	
	A12	5,990,145		Wehner et al.	11/1999	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sub>6</sub>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	A13	WO	93/13798			7/93		
	A14	WO	94/15958			7/94		
	A15	WO	95/15973		Cytel Corp.	6/15/1995		
	A16	WO	96/00581			1/96		
	A17	WO	96/06108			2/96		
	A18	WO	96/20216			7/96		
	A19	WO	95/14008		Cassella Farbwerke Mainkur AG	5/26/1995		
	A20	WO	93/18057			9/93		
	A21	EP	0449 079			10/91		
	A22	EP	0 796 855			9/97		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

+

+

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	3
-------	---	----	---

Application Number	Unassigned
Filing Date	Concurrently Herewith
First Named Inventor	Hans Ulrich STILZ et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	38005-0190

[illegible][illegible]

**Examiner  
Signature**

Date  
Considered

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box ☐ PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

+

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	Unassigned
		Filing Date	Concurrently Herewith
		First Named Inventor	Hans Ulrich STILZ et al.
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet 2 of 3	Attorney Docket Number	38005-0190	

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	A30	Ellices at al.. VCAM-1 on Activated Endothelium Interacts with the Leukocyte Integnn VLA-4 at a Site Distinct from the VLA-4/Fibronectin Binding Site' <u>Cell</u> 60:577-584 (1990)	
	A31	Issekutz at al.. Rat Blood Neutrophils Express Very Late Antigen 4 and it Mediates Migration to Arthritic Joint and Demiel Inflammation' <u>J. Exp. Med.</u> 183:2175-21 84 (1996)	
	A32	Kilger at al.. 'Molecular analysis of the physiological and pathophysiological role of $\alpha_4$ -integrins' <u>J. Mol. Med.</u> 73:347-354 (1995)	
	A33	Cronstein at al.. 'The Adhesion Molecules of Inflammation' Arthritis and Rheumatism 36. No. 2, pp. 147-157 (1993)	
	A34	Stilz et al. (CA 129:16396, abstract of DE 19647380), 1998	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.